AVDL - フラメル・テクノロジ―ズ (Avadel Pharmaceuticals plc) フラメル・テクノロジ―ズ

 AVDLのチャート


 AVDLの企業情報

symbol AVDL
会社名 Avadel Pharmaceuticals PLC (フラメル・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The Company offers various drug delivery platforms including Micropump LiquiTime Trigger Lock and Medusa. The Company offers its products in various categories including hospital including Bloxiverz Vazculep and Akovaz and pediatrics including Karbinal ER Cefaclor for Oral Suspension AcipHex Sprinkle and Flexichamber. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Vazculep is used to treat clinically hypotension resulting primarily from vasodilation in the setting of anesthesia. Akovaz is indicated to treat clinically hypotension in the setting of anesthesia. Cefaclor is indicated for the treatment of otitis media lower respiratory infections pharyngitis and tonsillitis urinary tract infections and skin and skin structure infections caused by susceptible organisms.   フラメル・テクノロジ―ズはフランスのバイオ医薬品メ―カ―。ポリマ―ベ―スの薬剤送達技術を開発。マイクロポンプ技術は、放出制御、味覚マスキング及び生物学的利用強化の応用で小分子薬の経口投与を実現。メデュ―サ技術は、治療用たんぱく質、ペプチド、その他の大小分子薬の注入後の制御放出を行う。グラクソ・スミスクラインなどとの共同開発を行う。   Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.
本社所在地 Block 10-1 Blanchardstown Corporate Park Ballycoolin Dublin 15 IRL
代表者氏名 Michael S. Anderson マイケル・S・アンダーソン
代表者役職名 Chief Executive Officer Director 最高経営責任者(CEO)
電話番号 +353 1-485-1200
設立年月日 33086
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 180人
url www.avadel.com
nasdaq_url https://www.nasdaq.com/symbol/avdl
adr_tso 41900230
EBITDA EBITDA(百万ドル) -8.02700
終値(lastsale) 4.46
時価総額(marketcap) 186875025.8
時価総額 時価総額(百万ドル) 171.32290
売上高 売上高(百万ドル) 136.95000
企業価値(EV) 企業価値(EV)(百万ドル) 175.41290
当期純利益 当期純利益(百万ドル) -5.75300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Avadel Pharmaceuticals PLC (ADR) revenues decreased 37% to $62.5M. Net loss totaled $15.7M vs. income of $54.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Interest Expense increase from $526K to $4.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $1.33 to -$0.41.

 AVDLのテクニカル分析


 AVDLのニュース

   A Bull Market Continues To Unfold On Avadel Pharmaceuticals plc (NASDAQ: AVDL), As It Continued To Rise 12.57% In Year-To-Date  2021/12/18 21:00:00 Marketing Sentinel
During the last session, Avadel Pharmaceuticals plc (NASDAQ:AVDL)s traded shares were 0.66 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stocks price was $7.52, reflecting an intraday loss of -3.47% or -$0.27. The 52-week high for the AVDL share is $11.59, that puts it down A Bull Market Continues To Unfold On Avadel Pharmaceuticals plc (NASDAQ: AVDL), As It Continued To Rise 12.57% In Year-To-Date Read More »
   Goldman Sachs Group Inc. Has $232,000 Stock Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL)  2021/12/11 09:10:43 Dakota Financial News
Goldman Sachs Group Inc. boosted its stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL) by 73.8% in the second quarter, HoldingsChannel reports. The firm owned 34,515 shares of the companys stock after buying an additional 14,661 shares during the period. Goldman Sachs Group Inc.s holdings in Avadel Pharmaceuticals were worth $232,000 as of its most recent SEC []
   Avadel Pharmaceuticals plc (AVDL) Should Be Considered Now, Despite A Loss Of -29.77% From High  2021/12/04 14:00:00 Stocks Register
Avadel Pharmaceuticals plc (NASDAQ:AVDL) concluded the trading at $8.14 on Friday, December 03 with a fall of -4.46% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $8.52 and 5Y monthly beta was reading 1.17 with its price kept floating in the Avadel Pharmaceuticals plc (AVDL) Should Be Considered Now, Despite A Loss Of -29.77% From High Read More »
   Squarepoint Ops LLC Increases Stock Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL)  2021/11/24 10:40:41 Dakota Financial News
Squarepoint Ops LLC lifted its stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL) by 135.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,162 shares of the companys stock after purchasing an additional 16,194 shares during the quarter. Squarepoint Ops LLCs holdings in Avadel Pharmaceuticals []
   Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Bought by LPL Financial LLC  2021/11/23 09:22:42 Dakota Financial News
LPL Financial LLC grew its holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) by 18.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,150 shares of the companys stock after buying an additional 3,000 shares during the quarter. LPL Financial LLCs holdings in Avadel []
   Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 8th  2021/11/01 12:00:00 Intrado Digital Media
DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company''s financial results for the third quarter ended September 30, 2021.
   Tri Locum Partners LP Boosts Stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL)  2021/10/26 15:32:46 Transcript Daily
Tri Locum Partners LP boosted its stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL) by 95.8% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 313,795 shares of the companys stock after buying an additional 153,539 shares during the quarter. Avadel Pharmaceuticals makes up about 0.7% []
   Avadel Pharmaceuticals plc (NASDAQ: AVDL) Could Make Significant Gains?  2021/10/25 12:00:00 Marketing Sentinel
In the last trading session, 1.07 million Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares changed hands as the companys beta touched 1.05. With the companys per share price at $8.14 changed hands at -$0.08 or -0.97% during last session, the market valuation stood at $480.83M. AVDLs last price was a discount, traded about -32.68% off its 52-week Avadel Pharmaceuticals plc (NASDAQ: AVDL) Could Make Significant Gains? Read More »
   Avadel Pharmaceuticals (NASDAQ:AVDL) Earns Buy Rating from Needham & Company LLC  2021/10/22 08:40:41 Dakota Financial News
Needham & Company LLC reaffirmed their buy rating on shares of Avadel Pharmaceuticals (NASDAQ:AVDL) in a research note published on Monday morning, AnalystRatings.com reports. They currently have a $16.00 price target on the stock. A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Avadel Pharmaceuticals […]
   Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap Up to $8.45  2021/10/21 07:26:41 Dakota Financial News
Avadel Pharmaceuticals plc (NASDAQ:AVDL)s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $8.45, but opened at $8.90. Avadel Pharmaceuticals shares last traded at $8.59, with a volume of 1,886 shares changing hands. AVDL has been the subject of several recent analyst reports. SVB Leerink reaffirmed a buy []
   Avadel's Formulated Sodium Oxybate Shows Improved Sleepiness, Sleep Quality In Narcolepsy Patients  2021/04/19 11:05:31 Benzinga
Avadel Pharmaceuticals Plc (NASDAQ: AVDL ) has announced the presentation of secondary endpoint data from the Phase 3 REST-ON trial evaluating FT218 once-nightly formulation of sodium oxybate (ON-SXB) for excessive daytime sleepiness and cataplexy in adults with narcolepsy. Narcolepsy is a chronic sleep disorder characterized by daytime drowsiness and sudden attacks of sleep. People with narcolepsy … Full story available on Benzinga.com
   Avadel Pharmaceuticals : Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy | MarketScreener  2021/03/01 13:01:57 MarketScreener
DUBLIN, Ireland, March 01, 2021 -- Avadel Pharmaceuticals plc today announced that the U.S. Food and Drug Administration has accepted for review the Company’s New Drug Application for… | March 1, 2021
   Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA  2020/12/16 13:00:00 GlobeNewswire
DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced the submission of its New Drug Application…
   Avadel Pharmaceuticals : Added to NASDAQ Biotechnology Index | MarketScreener  2020/12/15 13:03:18 MarketScreener
DUBLIN, Ireland, Dec. 15, 2020 -- Avadel Pharmaceuticals plc , a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive… | December 15, 2020
   Avadel Pharmaceuticals (NASDAQ:AVDL) Lowered to “Strong Sell” at BidaskClub  2020/10/25 08:06:43 Dakota Financial News
Avadel Pharmaceuticals (NASDAQ:AVDL) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Friday, BidAskClub reports. Several other research firms also recently weighed in on AVDL. Oppenheimer initiated coverage on Avadel Pharmaceuticals in a report on Thursday, July 30th. They issued a “buy” […]

 関連キーワード  (医薬品 米国株 フラメル・テクノロジ―ズ AVDL Avadel Pharmaceuticals plc)

 twitter  (公式ツイッターやCEOツイッターなど)